Neogenomics (NEO) Return on Capital Employed (2011 - 2026)
Neogenomics' (NEO) quarterly Return on Capital Employed came in at 5.5% in Q2 2026, up 273.0% YoY from 1.48% in Q2 2025, and up 34.32% on a QoQ basis from 8.38% in Q1 2026.
Neogenomics (NEO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Neogenomics (NEO) has 16 years of Return on Capital Employed data on file, last reported at 5.5% in Q2 2026.
- Quarterly Return on Capital Employed rose 273.0% year-over-year to 5.5% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 5.5% (up 273.0% YoY) and the FY2025 annual result came in at 8.21%, down 143.0% from the prior year.
- Return on Capital Employed grew to 5.5% in Q2 2026, from 8.38% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 5.5% in Q2 2026 to a low of 10.23% in Q3 2022.
- A 5-year average of 7.99% and a median of 8.19% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 830 bps — and 2023, when it surged 298 bps.
- Tracing NEO's Return on Capital Employed over 5 years: stood at 9.51% in 2022, then increased by 28 bps to 6.8% in 2023, then decreased by 1 bps to 6.88% in 2024, then slumped by 32 bps to 9.06% in 2025, then surged by 39 bps to 5.5% in 2026.
- The last three Return on Capital Employed figures came in at 5.5% (Q2 2026), 8.38% (Q1 2026), and 9.06% (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 8.30% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 6.42% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -13.91% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 14.57% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 10.49% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 68.60% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 17.55% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 49.80% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.97% |
| 10 | Neogenomics | 2.42 Bn | 2.28 Bn | 91.88 Mn | -5.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.50% |
| Mar 31, 2026 | -8.38% |
| Dec 31, 2025 | -9.06% |
| Sep 30, 2025 | -9.40% |
| Jun 30, 2025 | -8.23% |
| Mar 31, 2025 | -6.67% |
| Dec 31, 2024 | -6.88% |
| Sep 30, 2024 | -6.86% |
| Jun 30, 2024 | -7.05% |
| Mar 31, 2024 | -6.52% |
| Dec 31, 2023 | -6.80% |
| Sep 30, 2023 | -7.25% |
| Jun 30, 2023 | -8.14% |
| Mar 31, 2023 | -8.59% |
| Dec 31, 2022 | -9.51% |
| Sep 30, 2022 | -10.23% |
| Jun 30, 2022 | -10.01% |
| Mar 31, 2022 | -8.81% |
| Dec 31, 2021 | -6.59% |
| Sep 30, 2021 | -3.96% |